|
|
SAN FRANCISCO, CA and TAIPEI, TAIWAN / ACCESSWIRE / December 1, 2023 / HanchorBio Inc., a global clinicalstage biotechnology company focusing on the discovery and development of innovative immunobiomedicines to treat a wide variety of patients suffering from hardtotreat solid tumors or hematological malignancies, today announced the acceptance of poster presentation at the European Society for... Lire le communiqué |
|
| |
|
| |
|
|
SAN FRANCISCO, CA and TAIPEI, TAIWAN / ACCESSWIRE / October 3, 2023 / HanchorBio Inc., a global clinicalstage biotechnology company focusing on the discovery and development of innovative immunobiomedicines to treat a wide variety of patients suffering from different solid tumors or hematological malignancies with significant unmet medical needs, today announced that the first patient has been... Lire le communiqué |
|
| |
|
| |
|
|
SHANGHAI, CHINA and TAIPEI, TAIWAN / ACCESSWIRE / August 28, 2023 / HanchorBio Inc., a global clinicalstage biotechnology company focusing on the discovery and development of innovative immunobiomedicines, and Shanghai Henlius Biotech, Inc., a global biopharmaceutical company developing biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases, today announced that... Lire le communiqué |
|
| |
|
| |
|
|
HanchorBio Received IND Approval of HCB101 MultiRegional Clinical Trial By Taiwan FDATAIPEI, TAIWAN and SAN FRANCISCO, CA / ACCESSWIRE / July 24, 2023 / HanchorBio Inc., a global clinicalstage biotechnology company developing innovative immunobiomedicines, announced today that the Taiwan Food and Drug Administration TFDA has approved its investigational new drug IND application to initiate a... Lire le communiqué |
|
| |
|
| |
|
|
HanchorBio Received IND Clearance of HCB101 Multiregional Clinical Trial By US FDATAIPEI, TAIWAN and SAN FRANCISCO, CA / ACCESSWIRE / April 17, 2023 / HanchorBio Inc., a global clinicalstage biotechnology company developing innovative immunobiomedicines, announced today that the US. Food and Drug Administration FDA has cleared its investigational new drug IND application to initiate a... Lire le communiqué |
|
| |
|
| |
